HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MRNA
Moderna, Inc.
There isn't enough reported data to score MRNA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MRNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRNA's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MRNA PE Valuation
MRNA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MRNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MRNA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MRNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.09 | +$0.98 |
| Q2 2026 | -$7.98 | -$0.45 |
| Q1 2026 | -$8.14 | +$0.59 |
| Q4 2025 | -$7.26 | +$2.02 |
| Q3 2025 | -$8.07 | -$2.33 |
| Q2 2025 | -$7.53 | +$7.77 |
| Q1 2025 | -$8.73 | +$6.86 |
| Q4 2024 | -$9.28 | +$3.05 |
MRNA has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MRNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MRNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +29% |
| Q2 2026 | $145M | +2.1% |
| Q1 2026 | $389M | +260% |
| Q4 2025 | $678M | -30% |
| Q3 2025 | $1B | -45% |
| Q2 2025 | $142M | -41% |
| Q1 2025 | $108M | -35% |
| Q4 2024 | $966M | -66% |
MRNA's revenue is recovering but still below its 2021 peak: $1.3B last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.9% | +36 points |
| Q2 2026 | -562% | +77 points |
| Q1 2026 | -357% | +615 points |
| Q4 2025 | -126% | +2.6 points |
| Q3 2025 | -26% | -22 points |
| Q2 2025 | -639% | -73 points |
| Q1 2025 | -972% | -214 points |
| Q4 2024 | -129% | -129 points |
MRNA has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MRNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$726M |
| Q2 2026 | -$563M | +$359M |
| Q1 2026 | -$692M | +$462M |
| Q4 2025 | $891M | +194% |
| Q3 2025 | -$880M | +$837M |
| Q2 2025 | -$922M | +$534M |
| Q1 2025 | -$1.2B | +$31M |
| Q4 2024 | $303M | -25% |
MRNA has burned cash in six of the last eight quarters: −$2B over the past year, against −$2.7B the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MRNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MRNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +32M shares |
| 1 year | +10% | +40M shares |
| 3 years | +13% | +49M shares |
| 5 years | -0.9% | -4M shares |
| Available history | +30% | +99.2M shares |
MRNA has 430M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $1M |
| Q2 2023 | $628M |
| Q1 2023 | $526M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MRNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2023 | -4.4x | Net Cash |
| Q1 2023 | -0.7x | Net Cash |
| Q4 2022 | -0.3x | Net Cash |
| Q3 2022 | -0.2x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.3x | Net Cash |
| Q4 2021 | -0.5x | Net Cash |
| Q3 2021 | -0.7x | Net Cash |
MRNA has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MRNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.5 | Overbought |
| Stochastic | 85.1 | Overbought |
MRNA's weekly RSI is 71 (overbought) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MRNA PE vs Healthcare Sector
| Metric | MRNA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRNA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MRNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $217.4 | 6.4% above |
| 20 week MA | $145.4 | 59% above |
| 50 week MA | $86.0 | 169% above |
| 100 week MA | $57.8 | 300% above |
| 200 week MA | $82.4 | 181% above |
MRNA has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MRNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $123.4 | +532% |
| 2021 | $123.4 | $250.0 | +103% |
| 2022 | $250.0 | $199.1 | -20% |
| 2023 | $199.1 | $99.5 | -50% |
| 2024 | $99.5 | $40.1 | -60% |
| 2025 | $40.1 | $31.2 | -22% |
| 2026 YTD | $31.2 | $231.4 | +642% |
MRNA has the edge over HIMS on returns for 2026, with the stronger performance.